1 Predictors of Postviral Symptoms Following Epstein-Barr Virus-Associated Infectious

2 Mononucleosis in Young People – Data from the IMMUC Study

3

Maren Bodenhausen^{1*}, Jonas Geisperger^{1*}, Julia Lange de Luna¹, Johannes Wendl^{2,3}, 4 Alexander Hapfelmeier^{2,3}, Lina Schulte-Hillen¹, Rafael Pricoco^{1,17}, Nina Körber^{4,5,6}, Tanja 5 Bauer^{4,5,6}, Josef Mautner^{1,5,6}, Dieter Hoffmann^{4,6}, Peter Luppa^{6,7}, Silvia Egert-Schwender⁸, 6 Elfriede Nößner^{5,6}, Henri-Jacques Delecluse^{6,9}, Susanne Delecluse^{6,9}, Fabian Hauck^{6,10}, 7 Christine Falk^{6,11}, Thomas Schulz^{6,12,16}, Marc-Matthias Steinborn¹³, Andreas Bietenbeck¹⁴, 8 Alexandra Nieters^{6,15}, Lorenz Mihatsch¹**, Katrin Gerrer¹**, Uta Behrends^{1,5,6}**; for the IMMUC 9 Study Group*** 10 11 ¹ MRI Chronic Fatigue center for Young People, Children's Hospital Schwabing, TUM School 12

- 13 of Medicine and Health, Technical University of Munich (TUM), Munich, Germany
- ² Institute of General Practice and Health Services Research, TUM School of Medicine and
- 15 Health, TUM, Munich, Germany
- ³ Institute of AI and Informatics in Medicine, TUM School of Medicine and Health, TUM,
 Munich, Germany
- ⁴ Institute of Virology, TUM School of Medicine and Health, TUM, Munich, Germany
- 19 ⁵ Helmholtz Center Munich (HMGU), Munich, Germany
- 20 ⁶ German Center for Infection Research (DZIF), Germany
- ⁷ Institute of Clinical Chemistry and Pathobiochemistry, TUM, Munich, Germany
- 22 ⁸ Münchner Studienzentrum (MSZ), TUM, Munich, Germany
- ⁹ German Cancer Research Center (DKFZ), F100, Heidelberg, Germany
- ¹⁰ Dr. von Hauner Children's Hospital, Ludwig-Maximilians-Universität, Munich, Germany
- 25 ¹¹ Institute of Transplant Immunology, Hannover Medical School, Hannover, Germany
- 26 ¹² Institute of Virology, Medical School, Hannover, Germany
- ¹³ Department of Pediatric Radiology, Munich Municipal Hospital Group Schwabing, Munich,
- 28 Germany
- 29 ¹⁴ MVZ Labor Poing, Munich, Germany
- 30 ¹⁵ Center for Chronic Immunodeficiency (CCI), Freiburg, Germany
- 31 ¹⁶ Cluster of Excellence 2155 RESIST
- 32 ¹⁷ Institute of Medical Immunology, Charité, Berlin, Germany
- 33
- 34 * Bodenhauen M and Geisperger J contributed equally to this manuscript.
- 35 ** Behrends U, Gerrer K, and Mihatsch L contributed equally to this manuscript.
- 36 *** IMMUC Study Group team members are listed in the Acknowledgments. NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.
- 37

- 38 Keywords: Epstein-Barr virus, disease score, protraction, risk factor, fatigue
- 39 Running title: Predictors of Postviral Symptoms Following Epstein-Barr Virus-Associated
- 40 Infectious Mononucleosis in Young People Data from the IMMUC Study
- 41

42 **Corresponding author:**

- 43 Uta Behrends, M.D.
- 44 Children's Hospital
- 45 TUM School of Medicine and Health, Technical University of Munich,
- 46 Koelner Platz 1, 80804 Munich, Germany
- 47 Phone: +49 89 3068 2793
- 48 Fax: +49 89 3068 3800
- 49 E-mail: uta.behrends@mri.tum.de
- 50

51 Highlights:

- Severe gastrointestinal symptoms are associated with protracted course of Epstein Barr virus-associated Infectious Mononucleosis (EBV-IM).
- Signs of immune dysregulation prior to EBV-IM can indicate an increased risk of protracted symptoms.
- Greater number of initial symptoms helps to identify patients developing postviral
 fatigue.
- 58
- 59 Planned Journal: Journal of Clinical Virology (J. Clin. Virol.)
- 60 Number of characters/spaces of the title: 141 (max. not defined)
- 61 Number of key words: 5 (max. not defined, usually 3-5)
- 62 Number of words (abstract): 250 (max. 250)
- 63 Number of words (manuscript): 2459 (max. 2500)
- 64 Number of references: 38 (max. 40)
- 65 Number of figures: 5
- 66 Number of tables: 2
- 67 Number of supplementary tables: 2
- 68 Number of supplementary figures: 3
- 69 Number of supplementary materials: 2
- 70

71 **ABSTRACT** (250/250 words)

Background. Epstein-Barr virus-associated Infectious Mononucleosis (EBV-IM) is a common
disease following primary EBV infection in children and adolescents. While EBV-IM is mostly
self-limiting, symptoms like fatigue may persist over several months or even result in myalgic
encephalomyelitis/chronic fatigue syndrome (ME/CFS). This large clinical observational study
aimed at identifying risk factors for protracted courses of EBV-IM in young people.

Methods. A cohort of N=200 children, adolescents, and young adults with acute primary EBV infection was recruited from hospitals and private practices. Data on the patients' medical history as well as clinical and laboratory parameters were collected at a baseline visit (V1) within four weeks after symptom onset (T_{onset}) and at two follow-up visits (V2 and V3) one and six months after T_{onset}. Risk factors for protracted symptoms at V3 were modeled using multivariable logistic regressions.

Results. Protracted symptoms were observed in 55/183 (30.1%) and protracted fatigue in 34/181 (18.8%) patients at V3. A medical history indicating an increased susceptibility to infectious diseases as well as distinct severe IM symptoms, e.g. severe gastrointestinal symptoms, were significantly associated with protracted disease [OR: 2.31; P=0.011 and OR: 3.42; P=0.027] and with chronic fatigue [OR: 2.98; P=0.006 and OR: 3.54; P=0.034], respectively. Occurrence of twelve or more clinical and laboratory parameters until and including V1 discriminated between fatigue and no fatigue at V3 [OR 2.43, P=0.033].

Conclusion. A clinical history of immune dysregulation as well as distinct severe IM symptoms
 might predict protracted post-viral disease and thus help in the identification of young patients
 at risk.

93 INTRODUCTION

- 94 Infectious mononucleosis (IM) develops in up to 75% of adolescents and young adults after 95 primary infection with Epstein-Barr virus (EBV) [1]. Symptoms typically include fever, lymphadenopathy, tonsillopharyngitis, splenomegaly, and fatigue, and usually are self-limiting 96 97 within two weeks to three months [1]. However, acute complications such as kissing tonsils, 98 splenic rupture, or life-threatening hemophagocytic lymphohistiocytosis (HLH) [1, 2] can occur, 99 and lymphoproliferative disease can manifest in immunocompromised patients [3]. Moreover, 100 post-viral symptoms may persist for weeks or years and may fulfill the clinical criteria of myalgic 101 encephalomyelitis/chronic fatigue syndrome (ME/CFS) [4, 5], significantly compromising daily
- 102 activities [6].
- 103 Risk factors for long-term IM sequelae are still under investigation, and various scores have
- been published to assess IM severity, complexity, and protraction [7-13]. In a large cohort of
- 105 college students, physical symptoms and immune dysregulation-have been identified as risk
- 106 factors for ME/CFS following IM [14], and autonomic symptoms along with distinct immune
- 107 markers were suggested as predictors of severe ME/CFS [15].
- Here, we report on a novel IM scoring system and on candidate risk factors for protracted
 symptoms identified in the Munich Infectious Mononucleosis (IMMUC) study. This
 observational, prospective, longitudinal study investigates a comprehensive set of routine and
- 111 experimental data in 200 children, adolescents, and young adults with recent IM to identify
- biomarkers and causative factors of complicated disease trajectories, including chronic fatigue.

113 MATERIAL & METHODS

114 Ethics, Study Setting, and Inclusion Criteria: The IMMUC study was approved by the TUM 115 University Hospital Ethics Committee (No. 112/14) and adheres to the 1964 Declaration of Helsinki, its later amendments, and the ICH-GCP regulations. All participants and/or legal 116 117 guardians gave written informed consent. The study was registered at ClinicalTrials.gov 118 (NCT06002802). 200 participants with recent IM onset were prospectively recruited from 119 hospitals or private practices in or around Munich between February 2016 and June 2019 and 120 observed up to 12 months after IM onset. General, clinical, and virological inclusion criteria are 121 summarized in Tab. 1.

Study Visits, Study Periods and Study Data: Patients were seen at visit 1 (V1) within 28 122 123 days after onset (DAO) of IM (DAO 0=Tonset). V2 was scheduled at four to six weeks after Tonset and V3 at four to 12 months after Tonset. A defined set of virological (IMvir), clinical chemistry 124 125 (IM_{Lab}), and clinical (IM_{Clin}) features of IM was investigated at each visit. Additionally, medical 126 history data and external laboratory data were collected for the time periods before Tonset and 127 between Tonset, V1, and V2, to generate combined datasets for the history period (HP) before 128 T_{onset}, the very early period (VEP) from T_{onset} up to and including V1, and the early period (EP) 129 from T_{onset} up to and including V2 (**Fig. 1**). All visits included a structured interview, a physical 130 examination, and peripheral blood collection for routine (reported here) and experimental 131 (reported elsewhere) laboratory analyses. Splenic sonography was performed at V1 and V2 132 and in case of persistent splenomegaly at V3. For a detailed account of the collected study 133 data see Suppl. Methods, Suppl. Material M1, and Suppl. Material M2.

134 IM Scoring: A score was developed to grade severity (Smax), complexity (Cmax), and 135 protraction of individual IM features and overall IM at each visit and for each period (Tab. 2). 136 Up to five grades of severity (S0-5) were evaluated for each IM feature, and the highest severity 137 grade of all distinct features was used to grade the overall IM (Suppl. Mat. M2). By calculating 138 the number of IM features, complexity grades were determined for the overall IM (C0-C23), 139 IM_{Clin} (C0-15), and IM_{Lab} (C0-8) IM. Protraction grades were defined as P0 (feature/IM not 140 present anymore at V2 and V3), P1 (feature/IM present at V2 but not at V3), or P2 (feature/IM 141 present at V3). Since the clinical significance of mild lymphadenopathy and splenomegaly at 142 V3 was unclear, only S2-4 of the latter at V3 were counted as P2. The grading of fatigue at V3 143 differed from that at V1 and V2 due to an increasing clinical impact of fatigue over time.

Outcome Measures, Predictor Variables in Multivariable Logistic Regression Models:
Long-term IM protraction (P2-IM vs. P0/1-IM) or chronic fatigue (P2-fatigue vs. P0/1-fatigue)
were the binary outcome measures to be modelled. Predictor variables were either measured
repetitively at visits V1 and V2 (quantitative and categorized IM_{Vir}, IM_{Lab} and IM_{Clin} features)
and thus, included into the *visit-dependent* analyses (see below) or only once during the

periods HP, VEP, and/or EP (quantitative and categorized baseline patient characteristics as
well as Cmax-IM, -IM_{Lab}, -IM_{Clin}, Smax-IM, -IM_{Lab}, and -IM_{Clin} features) and thus included into
the *period-dependent* analyses (see below).

152 Sample Size Calculation: We expected approximately 10% of patients with P2-IM, and
 153 therefore, set the sample size to N=200 patients (Suppl. Methods).

154 Visit-Dependent Analyses: Each multivariable logistic regression model included one of the 155 predictor variables measured at V1 and V2, and sex and age as independent variables. Since 156 individual patients were measured repetitively, an interaction effect between the predictor 157 variable and DAO was included in each model. The effect of a predictor variable can thus be 158 described in dependence on DAO. These models also determined a time interval at which the 159 OR of the predictor variable was significantly different from 1. The robust Huber-White 160 estimator accounted for minor misspecifications of the model assumption due to repeated 161 measurements.

Period-Dependent Analyses: Each multivariable logistic regression model included one of
 the predictor variables measured once for either of the three periods: HP, VEP, or EP, and sex
 and age as independent variables. A grid search was used to find the optimal cut-off value for
 Cmax-IM and Cmax-IM_{clin} in terms of the area under the curve (AUC).

For the *visit*- and *period*-dependent analyses, models with less than five observations per independent variable per category variable of the outcome variable were discarded to prevent overfitting. Only significant results are presented here due to the abundance of variables investigated.

Other Statistical Analyses: Hypothesis tests were performed at exploratory 5% significance
levels. P-values are exploratory and thus not corrected for multiple testing . Analyses were
performed using R, version 4.1.3 (The R Foundation for Statistical Computing, Vienna, Austria)
[16].

- 174
- 175
- 176
- 177
- 178
- 179 180

181 **RESULTS**

- 182 Of 200 study participants assessed at V1, 194 and 183 attended V2 and V3, respectively (Fig.
- 183 **1A**). Study visits (V1, V2, V3) and study periods (HP, VEP, EP) are depicted in **Fig. 1B**.

184 Baseline Patient Characteristics: Detailed data are shown in Suppl. Table S1A to S1F. The 185 cohort included 92 children (1-11 years), 84 adolescents (12-17 years), and 24 adults (18-33 186 years). 54.5% patients were female. The mean age was 11.99±6.08 years (range: 1–33) (male: 187 11.76±6.89, female: 12.18±5.33; t-test: P=0.632). A history of increased susceptibility to 188 infections and/or immune dysregulation (ELVIS and/or GARFIELD criteria [17]) prior to IM was 189 reported by 47.5% of patients (Suppl. Table 1E). When asked for any fever or antibiotic 190 therapy during the six months prior to IM, 37.0% and 13.6% of patients provided positive 191 answers, respectively. 35.7% and 6.0% of patients remembered ≥1 or ≥2 family members with 192 a history of IM.

193 *Virological Features of IM*: Detailed data are provided in Fig. 2.

Severity, Complexity, and Protraction of IM: Comprehensive data on IM severity, complexity, and protraction are provided in Fig. 3A-C, Suppl. Fig. S1, Suppl. Fig. S2 and Suppl. Tab. S2. IM severity and complexity decreased from V1 to V3 as expected. At least one IM feature persisted in 52.3% at V2 (P1) and in 27.9% at V3 (P2) (Fig. 3C). 34 (18.8%) patients suffered from fatigue at V3, with mild fatigue (S1)-reported by 82.4% and moderate fatigue (S2) ("reduced education/work/club sports") by 17.6% of these patients (Fig. 3A,C).

200 Predictors for Long-Term Protraction (P2-IM):

- 201 Significant predictors of any IM feature at V3 (P2-IM) of the visit-dependent analyses are 202 shown in Fig. 4A. Early positivity for VCAp18 IgG was the only risk factor, with decreasing 203 effect over time (negative slope in Fig. 4A). Protective effects were also observed for early 204 atypical lymphocytosis (until 6 DAO), tonsillopharyngitis (until 9 DAO) and leukocytosis (until 205 4 DAO). Complexity of IM and IM_{Clin} were significant risk factors for P2-IM from DAO=6 and 206 DAO=5 onwards, respectively. Additional IM_{Clin} features predicted P2-IM, again with a delay of 207 few days after T_{onset} and depending on severity (positive slope in Fig. 4A). Considering the 208 AUC, the best predictor variables were complexity of IM_{Clin} (AUC 0.68), complexity of IM (AUC 209 0.66) and presence of other airway symptoms [S1-4 vs. S0] (AUC 0.62).
- Significant predictors of any IM feature at V3 (P2-IM) of the *period*-dependent analyses are shown in **Fig. 5A**. IM_{Clin} complexity in the VEP and EP were the best predictors in terms of the AUC. The ROC analysis indicated that a cut-off of \geq 10 and \geq 9 IM_{Clin} features during the VEP (OR 2.61, 95%-CI: [1.27, 5.37]) and EP (OR 2.63, 95%-CI: [1.37, 5.03]) provided the greatest AUCs for predicting P2-IM, respectively. Analogously, a cut-off of \geq 12 and \geq 13 IM features provided the greatest AUCs for the VEP (OR 2.47, 95%-CI: [1.26, 4.87]) and EP (OR 2.99,

216 95%-CI: [1.49, 5.98]), respectively. Interestingly, ≥1 positive ELVIS criterion was also identified

as a significant risk factor for P2-IM.

218 Predictors for Chronic Fatigue (P2-fatigue):

219 Significant predictors of fatigue at V3 (P2-fatigue) of the visit-dependent analyses are shown 220 in Fig. 4B. Fatigue was the most frequent IM feature at V3 (Suppl. Fig. S3E). It was, therefore, 221 not unexpected to find overlaps between predictors for P2-fatigue and P2-IM. The best 222 predictor for P2-fatigue regarding AUC was other airway symptoms which were significant risk 223 factors after DAO 17, with subsequent OR increase over time. Moreover, moderate to severe 224 GI symptoms and VCAp18 IgG detection in immunoblots were significant predictors with an 225 increasing and decreasing OR over time, respectively (Fig. 4B). We did not find a significant 226 visit-dependent effect of (very) early fatigue for P2-fatigue.

- 227 Significant predictors of fatigue at V3 (P2-fatigue) of the *period*-dependent analyses are shown
- in Fig. 5B. Early exanthema, early musculoskeletal symptoms, and ≥8 minor infections per
- 229 year (ELVIS criterion) prior to IM significantly predicted P2-fatigue. Early IM_{Clin} complexity was
- the best predictor (AUC 0.74) of the *period*-dependent analyses. ROC analysis indicated that
- 231 a cut-off of ≥12 IM features in the VEP (OR 2.43, 95%-CI: [1.07, 5.49]), and of ≥11 features in
- the EP (OR 3.39, 95%-CI: [1.41, 8.17]), as well as \geq 9 IM_{Clin} features in both periods (VEP: OR
- 233 2.47, 95%-CI: [1.14, 5.33]; EP: OR 4.41, 95%-CI: [1.90, 10.21]) resulted in the greatest AUC
- 234 for predicting fatigue at V3 (P2-fatigue), respectively. Early fatigue was not a significant
- predictor of P2-fatigue.

236 **DISCUSSION**

Long-term sequelae of IM, such as chronic fatigue, manifest in a significant number of cases [19, 20] and hit young people in a very vulnerable stage of their lives, indicating a high medical need for research on risk factors, prevention, and therapeutic strategies [18, 19]. To identify biomarkers and predictors of acute and long-term IM complications we implemented the longitudinal IMMUC study and report here on the first results from a cohort of 200 pediatric and young adult patients.

In line with published data, 72.1% of the patients had fully recovered five to eight months after IM onset [14]. Remarkably, 27.9% of the study participants showed protracted disease for more than four months after IM onset, including 18.8% cases with chronic fatigue. Several clinical and laboratory parameters were identified that may predict protracted IM and thus identify patients at risk.

Of note, IM complexity was a significant predictor of long-term protraction. Within the VEP and
 EP, 50.5% and 94% study participants presented with maximum IM complexity. Ten or more
 very early IM_{Clin} features predicted protracted disease at V3 and nine or more predicted chronic

251 fatigue. (Very) early IM_{Lab} features did not add any essential value to prediction accuracy.

252 Our findings are consistent with those reported by Cervia and colleagues, who identified the 253 complexity of coronavirus disease 2019 (COVID-19) in combination with other clinical and 254 laboratory characteristics as risk factors for post-acute COVID-19 syndromes [20]. It was 255 hypothesized that a greater number of symptoms during the acute infection, including 256 autonomic dysregulation, might reflect an initial immune (over)activation that results in 257 prolonged impaired health [15, 21]. Our results are also in line with reports indicating an 258 increased risk of ME/CFS in patients with more or more severe physical symptoms during the 259 acute infection [13, 14].

Patients with distinct inborn errors of immunity (IEI) carry an increased susceptibility to EBVassociated HLH or lymphoproliferative disorders [3]. However, little is known about clinical IEI warning signs as possible predictors of protracted IM. In a previous study, 60% of ME/CFS patients reported a history of recurrent infections [22]. Our IMMUC data demonstrate that \geq 1 major infection and \geq 8 minor infections per year predicted any IM feature or fatigue at V3, respectively. These findings suggest that patients with an increased susceptibility to infection should be closely monitored and offered timely advice after IM diagnosis.

In addition, chronic fatigue was predicted by (very) early exanthema and facial edema, possibly
 indicative of IM-associated vascular inflammation [23-25], and was associated with early
 musculoskeletal symptoms and (very) early moderate to severe GI symptoms. Interestingly,
 GI symptoms prior to IM have been associated with the development of ME/CFS [15]. Taken

together, these findings suggest that preexisting or early autonomic symptoms in the contextof IM might predict post-viral disease.

273 Remarkably, the detection of EBV VCAp18 IgG considered a late marker of primary EBV 274 infection [26], was identified as a significant predictor of any long-term protraction when 275 detected within the first three weeks after IM onset. This might indicate that individuals with a 276 long EBV incubation period prior to IM may face an increased risk of protracted disease, and 277 early immunoblot analysis might help in prediction. Early detection of EBV VCAp18 IgG has 278 been associated with a lower IM severity score by others but was not investigated as a 279 predictor of protracted disease [27]. Moreover, EBV VCAp18 IgM-mediated complement 280 deposition and EBV VCAp18 IgG-dependent cellular phagocytosis were positively associated 281 with IM severity [28], and complement activation was discussed in ME/CFS-associated 282 immune dysregulation [22].

Limitations. First, the results of the IMMUC scores might have been prone to interviewer bias.
 Second, most patients were recruited when initial IM symptoms had declined. Therefore,
 laboratory parameters at V1 may reflect a subacute stage of IM and remembered IM symptoms
 of the VEP might be influenced by recall bias. Third, the time period between V1 and follow up visits varied to match best with school schedules and family plans.

288

Conclusion. In this IMMUC study, we implemented a novel scoring system to evaluate IM severity, complexity, and protraction and identified several candidate predictors of chronic postviral disease that are easily assessed during routine diagnostics. This score may help identifying patients at risk and facilitate prompt medical provisioning. In addition, this score forms the basis for the analysis of diverse immunological parameters investigated in this cohort that might further improve prediction for long-term sequelae in young people with IM.

295 **NOTES**

296 Acknowledgments. The authors would like to thank the IMMUC Study Group team members 297 F. Fischer, M. Burggraf, P. Wallraven, R. Weggel, K. Bartl, L. Werny, K. Rautter, T. Hofberger, Y. Müller, H. Zietemann, E. Planatscher, J. Nückel, K. Michel, S. Strunz., J. Mücke, K. 298 299 Mittelstraß, M. Bach, F. Martin, L. Kramer, C. Richter, A. Yardim, and L. Beckert for their great study assistance. Furthermore we would like to thank patients and their families for 300 301 participating in the study, as well as all participating physicians for announcing the study and 302 transferring interested patients. Without their tremendous support this work would have not 303 been possible.

Author contributions. U.B. acquired funding, supervised and coordinated the study together 304 305 with K.G., U.B., M.B., J.G., A.H., S.S, N.K., T.B., J.M, D.H., P.L., S.E-S., H-J.D., S.D., F.H., 306 C.F., T.S., M-M.S., A.B., and K.G. designed the study. M.B., J.G., L.S-H., R.P., F.H., C.F., M-307 M.S., A.B., K.G., and U.B. recruited and visited the patients and acquired the data. M.B., J.G., 308 J.L.L., J.W., A.H., E.N., F.H., M-M.S., A.B., A.N., L.M., K.G., and U.B. analysed and interpreted 309 the data. M.B., J.G., L.M., J.L.L., A.H., A.N., K.G., and U.B. wrote the first version of the 310 manuscript. All authors read, edited, and commented on the draft. All authors approved the 311 final version of the manuscript to be published and agreed to be accountable for all aspects of 312 the work in ensuring that questions related to the accuracy or integrity of any part of the work 313 are appropriately investigated and resolved.

- Availability of data and materials. M.B., J.G., L.M., J.L.L., A.H., J.W., K.G., and U.B. have
 full access to all data and take responsibility for their integrity and accuracy.
- 316 *Ethical considerations.* The IMMUC study was approved by the Ethics Committee of the
 317 School of Medicine and Health of the Technical University of Munich (reference number:
 318 112/14).
- *Funding.* This work was funded by the German Center of Infection Research (DZIF) (grant
 numbers 07_905 and 07_909). Funding was acquired by U.B. and received by P.L., S.E-S.,
 A.H., D.H., F.H., J.M., T.B., H-J.D., C.F., and T.S..
- 322 Potential conflicts of interest. A.B. received lecture fees from Siemens. U.B. received 323 research grants for ME/CFS or EBV studies from the Federal Ministry of Education and 324 Research, the Federal Ministry of Health, the Bavarian State Ministry of Health and Care, the 325 Bavarian State Ministry of Science and the Arts, the German Center for Infection Research, 326 the People for Children (Menschen für Kinder) foundation, the Weidenhammer-Zoebele 327 Foundation, the Lost Voices Foundation, and the ME/CFS research foundation. All other 328 authors have no conflict of interest to declare.

Table 1. IMMUC Inclusion Criteria

A) G	eneral Criteria			
I	Age ≤ 39 years			
П	No pregnancy \leq 12 months prior to recruitment			
Ш	Written informed consent			
B) C	linical IM Criteria			
At le	ast 1 of the following IM symptoms with new onset			
≤ 28	days prior to recruitment			
I	Tonsillopharyngitis			
П	Lymphadenopathy			
III	Fever ≥ 38.5°C			
IV	Fatigue			
C) V	irological IM Criteria			
	ast 1 of I.1-4 at V1 <u>and</u> V1 <u>and</u> III at V1 or Tonset <u>and</u> IV			
I	 EBV DNA positive in cell fraction EBV DNA positive in plasma EBV VCA IgM positive in any test EBV VCA IgG positive in any test 			
П	EBNA-1 IgG maximal 1+ in immunoblot			
111	EBNA-1 IgG negative in any test			
IV	All data Tonset-V3 support EBV primary infection			

Table 2. IMMUC Scores

Severity	Severity of IM Features or IM				
S0-5	0 = not present 1 = very mild 2 = mild 3 = severe 4 = very severe 5 = associated with death due to IM				
Comple	exity of Clinical or Laboratory IM Features or IM				
C1-23	Defined as the number of IM features present				
Protrac	Protraction of IM Features or IM				
P0-2	0 = not present at V2 or V3 1 = present at V2 but not V3 or unknown at V3 2 = present at V3				

SUPPLEMENTARY METHODS

Study Data: Baseline patient characteristics included age, sex, body mass index (BMI), body height, serum titers (anti-diphtheria and anti-tetanus toxoid IgG, total IgA, IgM, IgG, IgE, vitamin D), and data from the general medical history of patients and families (Suppl. Tab. 1). The patient's medical history addressed clinical signs of pathological susceptibility to infections (ELVIS) [17] and immune dysregulation (GARFIELD) [17], failure to thrive, developmental delay, vaccination status, infectious diseases (influenza, herpes labialis, varicella, measles), allergies, asthma, cancer, transplantation, transfusions, exposure to farm animals, as well as specific events within 6 months before Tonset (fever, use of antibiotics/analgesics/ antiphlogistics, traveling to certain regions). The family's medical history addressed parent consanguinity, the number of siblings in the same household, as well as a history of IM, known inborn errors of immunity (IEI), cancer, neurodermatitis, autoimmune disease, allergies, and/or asthma (Suppl. Mat. M1). IM_{Clin} features included fever, fatigue, lymphadenopathy, tonsillopharyngitis, splenomegaly, facial edema, exanthema, other airway symptoms, other gastrointestinal (GI) symptoms, urogenital symptoms, bleeding and/or treatment for bleeding or anemia, neurological symptoms, musculoskeletal symptoms, hospitalization, and treatment for HLH (Suppl. Mat. M2); they were evaluated retrospectively and prospectively from Tonset until V3. IM_{Lab} features included lymphocytosis, neutropenia, anemia, thrombocytopenia, hyperferritinemia, hepatitis, nephropathy, and CRP elevation defined by age-adapted cut-off levels of blood count, transaminases (ASAT, ALAT), CRP, ferritin, creatinine, and (cystatin C if creatinine levels were elevated) in serum. IM_{Vir} features included EBV DNA in plasma (EBV_{Plasma}), cell fraction (EBV_{cells}), and oral washes (EBV_{oral}) evaluated by PCR (TaqManTM 7500, Thermo Fisher Scientific, Waltham, USA), as well as anti-EBV VCA IgM, anti-EBV VCA IgG, and anti-EBNA-1 IgG determined in serum by CMIA [ARCHITECT i1000SR[™], Abbot Laboratories, Chicago, USA]), and serum IgG against EAp54, EAp138, VCAp18, VCAp23, BZLF1 or EBNA-1 detected by immunoblot (ProfiBlotTM, Tecan Group Ltd., Männedorf, Switzerland).

Sample Size Calculation: With 20 expected P2 cases and a required minimum number of 5-10 observations in the less frequent outcome class, we could consistently estimate multivariable logistic regression models with 2-4 parameters [31, 32]. An unpaired two-sided t-test with a 5% significance level has 80% power to detect an effect size of 0.7 when the sample sizes in two groups are N=18 (P2) and N=180 (P0-1) in a total sample size of N=198, as expected (nQuery Advisor 7.0).

SUPPLEMENTARY TABLES

Supplementary Table S1A. Baseline Patient Characteristics – Sex and Age Distribution at Recruitment

Sex	Number/Total (%)
Male	91/200 (45.5%)
Female	109/200 (54.5%)
Age Groups	Number/Total (%)
Children 0-11 years	92/200 (46.0%)
Adolescents 12-17 years	84/200 (42.0%)
Adults 18-39 years	24/200 (12.0%)

Supplementary Table S1B. Baseline Patient Characteristics – Body Measures and Serum Titers

Characteristics	Number/Total (%)			
	Below Normal Range	Within Normal Range	Above Normal Range	
Body height [1]	4/198 (2.0%)	182/198 (91.9%)	12/198 (6.1%)	
Body mass index (BMI) [1]	9/200 (4.5%)	188/200 (94.0%)	3/200 (1.5%)	
Vitamin D [2]	68/200 (34.0%)	132/200 (66.0%)	0/200 (0.0%)	
Total IgE [2]	n/a	111/200 (55.5%)	89/200 (44.5%)	
Total IgA [2]	0/200 (0.0%)	156/200 (78.0%)	44/200 (22.0%)	
Total IgM [2]	3/200 (1.5%)	129/200 (64.5%)	68/200 (34.0%)	
Total IgG [2]	3/200 (1.5%)	162/200 (81.0%)	35/200 (17.5%)	
Anti-Diphtheria toxoid IgG [3]	0/200 (0.0%)	200/200 (100.0%)	n/a	
Anti-Tetanus toxoid IgG [3]	8/200 (4%)	192/200 (96.0%)	n/a	
Magnesium [2]	0/170 (0.0%)	143/170 (84.1%)	27/170 (15.9%)	

n/a: not applicable

[1] Age-adapted normal range of body measures (3th – 97th percentile) [33-35]

[2] Normal range vitamin D serum, total immunoglobulins (Ig) $(5^{th} - 95^{th} \text{ percentile})$ and magnesium serum [36]

[3] Normal range of vaccination titers according to the information of the standing committee on vaccination (STIKO) at the Robert Koch Institute (RKI), a department of the German Federal Health Agency [37], accessed on February 6th, 2024.

Vaccination Status	Number/Total (%)
Complete vaccination status [4]	177/199 (88.9%)
Incomplete vaccination status [4]	22/199 (11.1%)
Specific Infectious Diseases	Number/Total (%)
Herpes labialis	9/199 (4.5%)
Influenza	12/199 (6.0%)
Measles	5/199 (2.5%)
Varizella (chickenpox)	74/199 (37.2%)
Medical Interventions	Number/Total (%)
Transfusion	3/200 (1.5%)
Transplantation	1/200 (0.5%)
Others	Number/Total (%)
Allergies	58/200 (29.0%)
Asthma	16/200 (8.0%)
Developmental delay	1/200 (0.5%)
Type 1 diabetes mellitus	1/200 (0.5%)
Henoch-Schoenlein purpura	1/200 (0.5%)
Immune thrombocytopenic purpura	1/200 (0.5%)
Known failure to thrive	3/200 (1.5%)
Lichen sclerosis	1/200 (0.5%)
Malignant tumor	1/200 (0.5%)
Neurodermatitis	15/200 (7.5%)
Rheumatoid arthritis	1/200 (0.5%)

Supplementary Table S1C. Baseline Patient Characteristics – General Medical History

[4] Vaccination status according to the recommendations of the standing committee on vaccination (STIKO) at the Robert Koch Institute (RKI), a department of the German Federal Health Agency [38], accessed at the beginning of patient recruitment on February 11th, 2016.

Supplementary Table S1D. Baseline Patient Characteristics – Recent Medical History

Medical History Within 6 Months Before IM Onset	Number/Total (%)
Fever	74/200 (37.0%)
Travelling to Europe/Middle East	130/199 (65.3%)
Travelling Far East	6/199 (3.0%)
Exposure to farm animals	24/200 (12.0%)
Antibiotics	28/200 (14.0%)
Steroids (oral, intravenous)	1/200 (0.5%)
Analgetics/antiphlogistics	63/200 (31.5%)

Supplementary Table S1E. Baseline Patient Characteristics – Signs of Primary Immunodeficiency

Signs of Primary Immunodeficiency	Number/Total (%)
Known primary immunodeficiency	1/200 (0.5%)
ELVIS – at least one criterion [5]	77/200 (38.5%)
ELVIS – one criterion	60/200 (30.0%)
ELVIS – two criteria	13/200 (6.5%)
ELVIS – three criteria	3/200 (1.5%)
ELVIS – four criteria	1/200 (0.5%)
ELVIS – unusual pathogen	8/200 (4.0%)
ELVIS – multiple localization	4/199 (2.0%)
ELVIS – relapsing course	29/200 (14.5%)
ELVIS – unusual intensity	33/200 (16.5%)
ELVIS – increased sum of minor infections	25/200 (12.5%)
GARFIELD – at least one criterion [5]	37/200 (18.5%)
GARFIELD – one criterion	35/200 (17.5%)
GARFIELD – two criteria	2/200 (1.0%)
GARFIELD – granuloma	0/200 (0.0%)
GARFIELD – autoimmunity	5/200 (2.5%)
GARFIELD – recurring fever	7/200 (3.5%)
GARFIELD – eczema, including neurodermatitis	23/200 (11.5%)
GARFIELD – lymphoproliferation	3/200 (1.5%)
GARFIELD – chronic inflammatory bowel disease	1/200 (0.5%)
ELVIS or GARFIELD – at least one criterion [5]	95/200 (47.5%)
ELVIS and GARFIELD – at least one criterion of both [5]	19/200 (9.5%)

Supplementary Table S1F. Baseline Patient Characteristics – General Medical History of Family

Characteristics	Number/Total (%)		
Consanguineous parents	3/200 (1.5%)		
At least 1 sibling in the same household	158/200 (79.4%)		
1 sibling	108/200 (54.0%)		
2 siblings	36/200 (18.0%)		
≥ 3 siblings	14/200 (7.0%)		
Allergies	125/199 (62.8%)		
Allergic asthma	15/200 (7.5%)		
Infectious mononucleosis	71/199 (35.7%)		
1 family member	59/199 (29.6%)		
≥ 2 family members	12/199 (6.0%)		
Neurodermatitis	29/199 (14.6%)		
Classical autoimmune diseases	41/200 (20.5%)		
Cancer	126/199 (63.3%)		
Primary immunodeficiencies	1/199 (0.5%)		

Suppl. Table S2. Severity of IM features at Study Visits and Study Periods

IM Feature	Early Period (EP)	Very Early Period (VEP)	Visit 1 (V1)	Visit 2 (V2)	Visit 3 (V3)
	Number/Total (%)	Number/Total (%)	Number/Total (%)	Number/Total (%)	Number/Total (%)
IM _{Clin} Fea	tures				
Fever					
S0	55/200 (27.5%)	59/199 (29.6%)	164/196 (83.7%)	190/191 (99.5%)	178/179 (99.4%)
S1	55/200 (27.5%)	55/199 (27.6%)	23/196 (11.7%)	0/191 (0.0%)	1/179 (0.6%)
S2	90/200 (45.0%)	85/199 (42.7%)	9/196 (4.6%)	1/191 (0.5%)	0/179 (0.0%)
Fatigue					
S0	8/200 (4.00%)	14/200 (7.0%)	34/200 (17.0%)	102/193 (52.8%)	147/181 (81.2%)
S1	143/200 (71.5%)	142/200 (71.0%)	154/200 (77.0%)	91/193 (47.2%)	28/181 (15.5%)
S2	42/200 (21.0%)	38/200 (19.0%)	12/200 (6.0%)	0/193(0.0%)	6/181 (3.3%)
S3	7/200 (3.5%)	6/200 (3.0%)	0/200 (0.0%)	0/193(0.0%)	0/181 (0.0%)
Lymphad	enopathy				
S0	17/200 (8.5%)	20/200 (10.0%)	35/200 (17.5%)	126/192 (66.6%)	158/173 (91.3%)
S1	135/200 (67.5%)	134/200 (67.0%)	143/200 (71.5%)	66/192 (34.4%)	15/173 (8.7%)
S2	44/200 (22.0%)	43/200 (21.5%)	21/200 (10.5%)	0/192 (0.0%)	0/173 (0.0%)
S3	2/200 (1.0%)	2/200 (1.0%)	1/200 (0.5%)	0/192 (0.0%)	0/173 (0.0%)
S4	2/200 (1.0%)	1/200 (0.5%)	0/200 (0.0%)	0/192 (0.0%)	0/173 (0.0%)
Tonsillop	naryngitis		·		

S0	17/200 (8.5%)	20/200 (10.0%)	46/200 (23.0%)	166/192 (86.5%)	159/172 (92.4%)
S1	96/200 (48.0%)	94/200 (47.0%)	105/200 (52.5%)	25/192 (13.0%)	13/172 (7.6%)
S2	63/200 (31.5%)	63/200 (31.5%)	39/200 (19.5%)	1/192 (0.5%)	0/172 (0.0%)
S3	21/200 (10.5%)	20/200 (10.0%)	7/200 (3.5%)	0/192 (0.0%)	0/172 (0.0%)
S4	3/200 (1.5%)	3/200 (1.5%)	3/200 (1.5%)	0/192(0.0%)	0/172 (0.0%)
Splenon	negaly				
S0	48/195 (24.6%)	48/189 (25.4%)	51/186 (27.4%)	111/183 (60.7%)	26/37 (70.3%)
S1	90/195 (46.2%)	89/189 (47.1%)	84/186 (45.2%)	60/183(32.8%)	11/37 (29.7%)
S2	56/195 (28.7%)	51/189 (27.0%)	50/186 (26.9%)	12/183 (6.6%)	0/37 (0.0%)
S4	1/195 (0.5%)	1/189 (0.5%)	1/186 (0.5%)	0/183 (0.0%)	0/37 (0.0%)
Facial E	dema	ł		ł	
S0	113/200 (56.5%)	114/200 (57.0%)	150/200 (75.0%)	191/194 (98.5%)	181/183 (98.9%)
S1	60/200 (30.0%)	61/200 (30.5%)	41/200 (20.5%)	3/194 (1.5%)	2/183 (1.1%)
S2	22/200 (11.0%)	21/200 (10.5%)	7/200 (3.5%)	0/194 (0.0%)	0/183 (0.0%)
S3	5/200 (2.5%)	4/200 (2.0%)	2/200 (1.0%)	0/194 (0.0%)	0/183 (0.0%)
Exanthe	ma			I	
S0	145/200 (72.5%)	154/198 (77.8%)	171/197 (86.8%)	181/190 (95.3%)	179/180 (99.4%)
S1	28/200 (14.0%)	21/198 (10.6%)	9/197 (4.6%)	6/190 (3.2%)	1/180 (0.6%)
S2	21/200 (10.5%)	17/198 (8.6%)	13/197 (6.6%)	3/190 (1.6%)	0/180 (0.0%)
S3	6/200 (3.0%)	6/198 (3.0%)	4/197 (2.0%)	0/190 (0.0%)	0/180 (0.0%)
S4	0/200 (0.0%)	0/198 (0.0%)	0/197 (0.0%)	0/190 (0.0%)	0/180 (0.0%)
Bleeding	and/or Treatment for	Bleeding or Anemia	l	I	
S0	189/200 (94.5%)	190/200 (95.0%)	196/198 (99.0%)	192/193 (99.5%)	181/181 (100.0%)
S1	11/200 (5.5%)	10/200 (5.0%)	2/198 (1.0%)	1/193 (0.5%)	0/181 (0.0%)
S2	0/200 (0.0%)	0/200 (0.0%)	0/198 (0.0%)	0/193 (0.0%)	0/181 (0.0%)
S3	0/200 (0.0%)	0/200 (0.0%)	0/198 (0.0%)	0/193 (0.0%)	0/181 (0.0%)
S4	0/200 (0.0%)	0/200 (0.0%)	0/198 (0.0%)	0/193 (0.0%)	0/181 (0.0%)
Other Ai	rway Symptoms	I		I	L
S0	41/199 (20.6%)	43/196 (21.9%)	79/194 (40.7%)	162/191 (84.8%)	151/162 (93.2%)
S1	141/199 (70.9%)	137/196 (69.9%)	108/194 (55.7%)	28/191 (14.7%)	11/162 (6.8%)
S2	7/199 (3.5%)	7/196 (3.6%)	3/194 (1.5%)	1/191 (0.5%)	0/162 (0.0%)
S3	8/199 (4.0%)	8/196 (4.1%)	4/194 (2.1%)	0/191 (0.0%)	0/162 (0.0%)
S4	2/199 (1.0%)	1/196 (0.5%)	0/194 (0.0%)	0/191 (0.0%)	0/162 (0.0%)
Other G	astrointestinal Sympto	ms		I	
S0	57/200 (28.5%)	66/199 (33.2%)	132/198 (66.7%)	171/191 (89.5%)	170/177 (96.0%)
S1	121/200 (60.5%)	116/199 (58.3%)	57/198 (28.8%)	18/191 (9.4%)	7/177 (4.0%)
S2	10/200 (5.0%)	8/199 (4.0%)	3/198 (1.5%)	1/191 (0.5%)	0/177 (0.0%)
S3	12/200 (6.0%)	9/199 (4.5%)	6/198 (3.0%)	1/191 (0.5%)	0/177 (0.0%)
S4	0/200 (0.0%)	0/199 (0.0%)	0/198 (0.0%)	0/191 (0.0%)	0/177 (0.0%)
Urogeni	al Symptoms	1		L	1
S0	187/199 (94.0%)	185/197 (93.9%)	192/197 (97.5%)	191/193 (99.0%)	178/180 (98.9%)
S1	10/199 (5.0%)	10/197 (5.1%)	4/197 (2.0%)	2/193 (1.0%)	2/180 (1.1%)
	1			1	1

60	2/100 (1.09/)	2/107 (1.00()	1/107 (0 50()	0/102 (0.09/)	0/190 (0.09/)
S2	2/199 (1.0%)	2/197 (1.0%)	1/197 (0.5%)	0/193 (0.0%)	0/180 (0.0%)
S3	0/199 (0.0%)	0/197 (0.0%)	0/197 (0.0%)	0/193 (0.0%)	0/180 (0.0%)
S4	0/199 (0.0%)	0/197 (0.0%)	0/197 (0.0%)	0/193 (0.0%)	0/180 (0.0%)
	gical Symptoms			· · · · · · · · · · · · · · · · · · ·	
S0	56/199 (28.1%)	62/196 (31.6%)	135/196 (68.9%)	172/191 (90.0%)	166/179 (92.7%)
S1	138/199 (69.3%)	129/196 (65.8%)	58/196 (29.6%)	18/191 (9.4%)	13/179 (7.3%)
S2	2/199 (1.0%)	2/196 (1.0%)	2/196 (1.0%)	0/191 (0.0%)	0/179 (0.0%)
S3	1/199 (0.5%)	1/196 (0.5%)	0/196 (0.0%)	0/191 (0.0%)	0/179 (0.0%)
S4	2/199 (1.0%)	2/196 (1.0%)	1/196 (0.5%)	1/191 (0.5%)	0/179 (0.0%)
Musculo	oskeletal Symptoms				
S0	103/199 (51.8%)	123/197 (62.4%)	168/197 (85.3%)	180/192 (93.8%)	174/178 (97.8%)
S1	83/199 (41.7%)	63/197 (32.0%)	24/197 (12.2%)	12/192 (6.3%)	4/178 (2.2%)
S2	11/199 (5.5%)	9/197 (4.6%)	5/197 (2.5%)	0/192 (0.0%)	1/178 (0.6%)
S3	2/199 (1.0%)	2/197 (1.0%)	0/197 (0.0%)	0/192 (0.0%)	0/178 (0.0%)
Imminer	nt or Treatment for Her	maphagocytic Lympl	nohistiocytosis (HLH)		
S0	199/200 (99.5%)	199/200 (99.5%)	199/200 (99.5%)	193/194 (99.5%)	182/183 (99.5%)
S3	0/200 (0.0%)	0/200 (0.0%)	0/200 (0.0%)	1/194 (0.5%)	1/183 (0.5%)
S4	1/200 (0.5%)	1/200 (0.5%)	1/200 (0.5%)	0/194 (0.0%)	0/183 (0.0%)
Hospital	lization				
S0	111/200 (55.5%)	115/200 (57.5%)	134/200 (67.0%)	194/194 (100.0%)	181/182 (99.5%)
S2	81/200 (40.5%)	81/200 (40.5%)	62/200 (31.0%)	0/194 (0.0%)	0/182 (0.0%)
S3	7/200 (3.5%)	3/200 (1.5%)	4/200 (2.0%)	0/194 (0.0%)	1/182 (0.5%)
S4	1/200 (0.5%)	1/200 (0.5%)	0/200 (0.0%)	0/194 (0.0%)	0/182 (0.0%)
$IM_{Lab}Fe$	atures				
Lympho	cytosis				
S0	155/200 (77.5%)	164/200 (82.0%)	178/195 (91.3%)	183/185 (98.9%)	175/175 (100.0%)
S1	45/200 (22.5%)	36/200 (18.0%)	17/195 (8.7%)	2/185 (1.1%)	0/175 (0.0%)
Neutrop	enia				
S0	116/198 (58.6%)	151/197 (76.6%)	159/192 (82.8%)	157/183 (85.8%)	170/173 (98.3%)
S1	54/198 (27.3%)	35/197 (17.8%)	28/192 (14.6%)	22/183 (12.0%)	2/173 (1.2%)
S2	27/198 (13.6%)	10/197 (5.1%)	5/192 (2.6%)	4/183 (2.2%)	1/173 (0.6%)
S3	1/198 (0.5%)	1/197 (0.5%)	0/192 (0.0%)	0/183 (0.0%)	0/173 (0.0%)
Anemia					
S0	190/198 (96.0%)	190/197 (96.4%)	187/192 (97.4%)	182/184 (98.9%)	173/174 (99.4%)
S1	3/198 (1.5%)	3/197 (1.5%)	3/192 (1.6%)	1/184 (0.5%)	1/174 (0.6%)
S2	5/198 (2.5%)	4/197 (2.0%)	2/192 (1.0%)	1/184 (0.5%)	0/174 (0.0%)
S3	0/198 (0.0%)	0/197 (0.0%)	0/192 (0.0%)	0/184 (0.0%)	0/174 (0.0%)
S4	0/198 (0.0%)	0/197 (0.0%)	0/192 (0.0%)	0/184 (0.0%)	0/174 (0.0%)
	ocytopenia		· · /		
S0	148/199 (74.4%)	151/199 (75.9%)	176/194 (90.7%)	184/186 (98.9%)	173 /175 (98.9%)
S1	50/199 (25.1%)	47/199 (23.6%)	17/194 (8.8%)	1/186 (0.5%)	2/175 (1.1%)
S2	0/199 (0.0%)	0/199 (0.0%)	0/194 (0.0%)	0/186 (0.0%)	0/175 (0.0%)
	0, 100 (0.070)	0,100 (0.070)	0, 10 1 (0.070)	0, 100 (0.070)	10

S3	0/199 (0.0%)	0/199 (0.0%)	0/194 (0.0%)	0/186 (0.0%)	0/175 (0.0%)
S4	1/199 (0.5%)	1/199 (0.5%)	1/194 (0.5%)	1/186 (0.5%)	0/175 (0.0%)
Hyperfer	ritinemia				
S0	124/200 (62.0%)	122/192 (63.5%)	129/195 (66.2%)	180/186 (96.8%)	175/176 (99.4%)
S1	56/200 (28.0%)	51/192 (26.6%)	50/195 (25.6%)	5/186 (2.7%)	0/176 (0.0%)
S2	15/200 (7.5%)	14/192 (7.3%)	14/195 (7.2%)	1/186 (0.5%)	1/176 (0.6%)
S3	4/200 (2.0%)	4/192 (2.1%)	1/195 (0.5%)	0/186 (0.0%)	0/176 (0.0%)
S4	1/200 (0.5%)	1/192 (0.5%)	1/195 (0.5%)	0/186 (0.0%)	0/176 (0.0%)
Hepatitis	or Cholangitis				
S0	70/200 (35.0%)	74/200 (37.0%)	86/196 (43.9%)	155/186 (83.3%)	174/174 (100.0%)
S1	105/200 (52.5%)	101/200 (50.5%)	97/196 (49.5%)	31/186 (16.7%)	0/174 (0.0%)
S2	19/200 (9.5%)	19/200 (9.5%)	10/196 (5.1%)	0/186 (0.0%)	0/174 (0.0%)
S3	6/200 (3.0%)	6/200 (3.0%)	3/196 (1.5%)	0/186 (0.0%)	0/174 (0.0%)
S4	0/200 (0.0%)	0/200 (0.0%)	0/196 (0.0%)	0/186 (0.0%)	0/174 (0.0%)
Nephrop	athy			•	
S0	197/199 (99.0%)	194/195 (99.5%)	193/194 (99.5%)	186/186 (100.0%)	173/173 (100.0%)
S1	1/199 (0.5%)	0/195 (0.0%)	0/194(0.0%)	0/186 (0.0%)	0/173 (0.0%)
S2	1/199 (0.5%)	1/195 (0.5%)	1/194 (0.5%)	0/186 (0.0%)	0/173 (0.0%)
S3	0/199 (0.0%)	0/195 (0.0%)	0/194 (0.0%)	0/186 (0.0%)	0/173 (0.0%)
Elevation	of C-reactive Protein			•	
S0	83/200 (41.5%)	86/200 (43.0%)	123/196 (62.8%)	180/187 (96.3%)	175/175 (100.0%)
S1	106/200 (53.0%)	105/200 (52.5%)	72/196 (36.7%)	7/187 (3.7%)	0/175 (0.0%)
S2	11/200 (5.5%)	9/200 (4.5%)	1/196 (0.5%)	0/187 (0.0%)	0/175 (0.0%)
S3	0/200 (0.0%)	0/200 (0.0%)	0/196 (0.0%)	0/187 (0.0%)	0/175 (0.0%)

FIGURE LEGENDS

Figure 1 – Study Setting with Number of Participants (A), Study Visits, and Study Periods (B).

(A) Two hundred patients were recruited, of which 194 were seen at visit 2 (V2) and 183 at visit 3 (V3), with two patients not seen at V2 but again at V3 and another four dropping out before V2. (B) The X-axis depicts the days after onset (DAO) of IM from day 0 up to day 349 when the last patient was seen for V3. V1 was scheduled up to 28 DAO, V2 23-52 DAO, and V3 142-349 DAO. Time periods were defined as medical history period (HP) as the time period before T_{onset} , i.e., 0 DAO, the very early period (VEP) from IM onset (T_{onset}) until and including V1 and the early period (EP) from T_{onset} until and including V2.

Figure 2 – Virological IM Features

Alluvial plots of virological features of IM (IM_{Vir}). The first row shows the results of the chemiluminescent microparticle immunoassay (CMIA) for EBNA1 IgG, EBV VCA IgG, and EBV VCA IgM. The second row shows the PCR results for detecting EBV DNA in cell fraction, in plasma, and in oral washes. The third and fourth rows show the Immunoblot results for EBNA1 IgG, EBV VCAp18 IgG, EBV BZLF1 IgG, EBV VCAp23 IgG, EBV EAp138 IgG, and EBV EAp54 IgG. Red depicts a negative result, yellow is an intermediate, and green is a positive result of the respective method. Grey indicates missing data. The bands between the stacked columns show the development of the test results. CMIA at V1, V2, and V3 detected VCA IgM in 93.5%, 83.2%, and 26.6%, VCA IgG in 81.5%, 91.9%, and 99.4%, and EBNA-1 IgG in 2.5%, 2.7% and 86.5% cases, respectively, indicating negative VCA IgM and/or IgG at V1, negative EBNA-1 IgG at V3, and persisting VCA IgM at V3 in some cases as expected. Immunoblots at V1, V2, and V3 showed IgG against VCAp18 in 9.6%, 15.1% and 98.9% against EAp54 in 76.6%, 77.8% and 48.3%, against EAp138 in 33.5%, 31.4% and 41.6% patients, and against at least one EA in 80,7% 81,6% and 60,7% respectively, demonstrating early VCAp18 IgG and late EA IgG in a significant number of patients. PCR at V1, V2, and V3 revealed EBV_{oral} in 86.5%, 66.7% and 38.2%, EBV_{cells} in 91.8%, 55.1% and 42.1% and EBV_{plasma} in 39.3%, 0.0% and 0.6% patients, respectively, with detectable EBV DNA in recovered cases as expected. The highest viral load at V1, V2, and V3 were 38,100.0 Geq/10⁵, 8,190.0 Geq/10⁵, and 2,330.0 Geq/10⁵ for EBV_{cells}, and 130,000.0 IU/mI, 0 IU/mI and 530.0 IU/ml for EBV_{plasma}, indicating that very high viral load in peripheral blood is short-lived as described [8].

Figure 3 – Main Clinical Outcomes

Summary of outcomes measured for the very early period (VEP, grey), the early period (EP, grey), and at the visits 1 - 3 (colored). The severity of all symptoms, according to the IMMUC score (A), includes clinical and laboratory symptoms. The violin plot of the complexity score (B) shows the number of observed clinical and laboratory symptoms. Protraction (C) indicates if patients had symptoms until and including V1 (P0), V2 (P1), or V3 (P2).

Figure 4 – Results of the Visit-Dependent Analyses

Multivariable logistic regression models were used to model the effect of each visit-dependent variable for protraction (P2-IM) (A) and fatigue at V3 (P2-fatigue) (B). A separate model was estimated for each predictor variable, with sex and age as additional covariables. Each subplot shows how the log OR (black line) changes depending on the days after the onset (DAO) of IM symptoms. The dashed lines show the pointwise 95%-confidence band. A log OR of 0 is equivalent to an OR of 1. Thus, whenever the zero line (grey) is not included in the 95%-confidence band, the OR is significantly different from 1. The DAO where the zero line intersects the boundary of the 95%-confidence band is marked by a red cross, with the respective DAO in parenthesis. The blue rug shows when the respective (multiple) measurements were taken. The respective AUC of each model and the number of measurements included in the model is shown in the top left corner of each plot.

Figure 5 – Results of the Period-Dependent Analyses

Forest plot of the significant results of the period-dependent analyses. Multivariable logistic regression models were used to model the effect of each visit-dependent variable for protraction (P2-IM) (A) and fatigue at V3 (P2-fatigue) (B). A separate model was estimated for each predictor variable, with sex and age as additional covariables. The number of observations and AUC are provided in adjacent columns. HP indicates the medical history period prior to T_{onset} , VEP the very early period from T_{onset} up to and including V1, and EP the early period from T_{onset} up to and including V2.

SUPPLEMENTARY FIGURE LEGENDS

Supplementary Figure S1 – Clinical and Laboratory IMMUC Severity Scores

The relative frequency of the severity of clinical (IM_{Clin}) (A) and laboratory symptoms (IM_{Lab}) (B) for the very early period (VEP, grey), the early period (EP, grey), and the visits 1 – 3 (colored) are shown.

Supplementary Figure S2 – Clinical and Laboratory IMMUC Complexity Scores

The complexity of clinical (IM_{Clin}) (A) and laboratory symptoms (IM_{Lab}) (B) during the very early period (VEP, grey), the early period (EP, grey), and the visits 1 - 3 (colored) are shown.

Supplementary Figure S3 – IMMUC Severity Scores of Each Symptom

The severity of individual symptoms for the very early period (VEP, A), the early period (EP, B), and at the visits V1 (C), V2 (D), and V3 (E) are shown. n/N (%) indicates the number of patients with the symptom relative to the number of patients where the respective symptom was assessed.

REFERENCES

- 1. Leung, A.K.C., J.M. Lam, and B. Barankin, *Infectious Mononucleosis: An Updated Review.* Curr Pediatr Rev, 2024. **20**(3): p. 305-322.
- 2. Marsh, R.A., *Epstein-Barr virus and hemophagocytic lymphohistiocytosis*. Front Immunol, 2017. **8**: p. 1902.
- 3. Damania, B. and C. Munz, *Immunodeficiencies that predispose to pathologies by human oncogenic gamma-herpesviruses.* FEMS Microbiol Rev, 2019. **43**(2): p. 181-192.
- 4. Pedersen, M., et al., *Predictors of chronic fatigue in adolescents six months after acute Epstein-Barr virus infection: A prospective cohort study.* Brain Behav Immun, 2019. **75**: p. 94-100.
- 5. Conroy, K.E., M.F. Islam, and L.A. Jason, *Evaluating case diagnostic criteria for myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS): toward an empirical case definition.* Disabil Rehabil, 2022: p. 1-8.
- 6. CDC. *Myalgic Encephalomyelitis/Chronic Fatigue Syndrome*. 2021 [cited 2023 2023/11/08]; Available from: <u>https://www.cdc.gov/me-cfs/symptoms-diagnosis/symptoms.html</u>.
- 7. Balfour, H.H., Jr., et al., *A prospective clinical study of Epstein-Barr virus and host interactions during acute infectious mononucleosis.* J Infect Dis, 2005. **192**(9): p. 1505-12.
- 8. Balfour, H.H., Jr., et al., *Behavioral, virologic, and immunologic factors associated with acquisition and severity of primary Epstein-Barr virus infection in university students.* J Infect Dis, 2013. **207**(1): p. 80-8.
- 9. Odame, J., et al., *Correlates of illness severity in infectious mononucleosis.* Can J Infect Dis Med Microbiol, 2014. **25**(5): p. 277-80.
- 10. Buchwald, D.S., et al., *Acute infectious mononucleosis: characteristics of patients who report failure to recover.* Am J Med, 2000. **109**(7): p. 531-7.
- 11. Wemel, A.C., et al., *Severe infectious mononucleosis in immunocompetent adults.* Med Mal Infect, 2017. **47**(8): p. 540-545.

- 12. Aslan, N., et al., Severity of acute infectious mononucleosis correlates with crossreactive Influenza CD8 T-Cell receptor repertoires. mBio, 2017. **8**(6).
- 13. Katz, B.Z., et al., *A validated scale for assessing the severity of acute infectious mononucleosis.* J Pediatr, 2019. **209**: p. 130-133.
- 14. Jason, L.A., et al., *Risks for developing myalgic encephalomyelitis/chronic fatigue syndrome in college students following infectious mononucleosis: A prospective cohort study.* Clin Infect Dis, 2021. **73**(11): p. e3740-e3746.
- Jason, L.A., et al., Predictors for developing severe myalgic encephalomyelitis/chronic fatigue syndrome following infectious mononucleosis. J Rehabil Ther, 2022. 4(1): p. 1-5.
- 16. Team, R.C. *The R project for statistical computing*. 2022; Available from: <u>https://www.r-project.org</u>.
- 17. Ehl, S., *Immundefekte neue Entwicklungen, die Kinderärzte kennen sollten.* Monatsschr Kinderheilkd 2023. **171**: p. 698–705.
- 18. Hocqueloux, L., et al., *The high burden of hospitalizations for primary EBV infection: a 6-year prospective survey in a French hospital.* Clin Microbiol Infect, 2015. **21**(11): p. 1041 e1-7.
- 19. Pheby, D.F.H., et al., *The Role of Prevention in Reducing the Economic Impact of ME/CFS in Europe: A Report from the Socioeconomics Working Group of the European Network on ME/CFS (EUROMENE).* Medicina (Kaunas), 2021. **57**(4).
- 20. Cervia, C., et al., *Immunoglobulin signature predicts risk of post-acute COVID-19 syndrome.* Nat Commun, 2022. **13**(1): p. 446.
- 21. Katz, B.Z., et al., Autonomic symptoms at baseline and following infectious mononucleosis in a prospective cohort of adolescents. Arch Pediatr Adolesc Med, 2011. **165**(8): p. 765-6.
- 22. Lutz, L., et al., Evaluation of Immune Dysregulation in an Austrian Patient Cohort Suffering from Myalgic Encephalomyelitis/Chronic Fatigue Syndrome. Biomolecules, 2021. **11**(9).
- 23. Guillevin, L., *Infections in vasculitis.* Best Pract Res Clin Rheumatol, 2013. **27**(1): p. 19-31.
- 24. Yang, Y. and F. Gao, *Clinical characteristics of primary and reactivated Epstein-Barr virus infection in children.* J Med Virol, 2020.
- 25. Ciccarese, G., et al., *Dermatological manifestations of Epstein-Barr virus systemic infection: a case report and literature review.* Int J Dermatol, 2020. **59**(10): p. 1202-1209.
- 26. Balfour, H.H., Jr., S.K. Dunmire, and K.A. Hogquist, *Infectious mononucleosis.* Clin Transl Immunology, 2015. **4**(2): p. e33.
- 27. Geris, J.M., et al., *Rapid antibody responses to Epstein-Barr virus correlate with reduced severity of primary infection.* J Clin Virol, 2022. **155**: p. 105267.
- 28. Karsten, C.B., et al., *Evolution of functional antibodies following acute Epstein-Barr virus infection.* PLoS Pathog, 2022. **18**(9): p. e1010738.
- 29. Donzel, M., et al., *Lymphomas associated with Epstein-Barr virus infection in 2020: Results from a large, unselected case series in France.* EClinicalMedicine, 2022. **54**: p. 101674.
- 30. Soldan, S.S. and P.M. Lieberman, *Epstein-Barr virus and multiple sclerosis*. Nat Rev Microbiol, 2023. **21**(1): p. 51-64.
- 31. Harrell, F.E.J., *Regression modeling strategies*. 2 ed. 2015: Springer Cham.
- 32. Whitehead, J., *Sample size calculations for ordered categorical data.* Stat Med, 1993. **12**(24): p. 2257-71.
- 33. Hesse, V., et al., Längsschnittstudie des aktuellen Wachstums 0- bis 6-jähriger deutscher Kinder: Teil 1. Monatsschr Kinderheilkd, 2016. **164**: p. 478-496.
- 34. Kromeyer-Hauschild, K., et al., *Perzentile für den Body-mass-Index für das Kindesund Jugendalter unter Heranziehung verschiedener deutscher Stichproben.* Monatsschr Kinderheilkd, 2001. **149**: p. 807-818.
- 35. Hemmelmann, C., et al., Perzentilen des Body-Mass-Index auch für 18- bis 80-Jährige? Daten der Nationalen Verzehrsstudie II [Percentiles of body mass index of

18-80-year-old German adults based on data from the Second National Nutrition Survey]. Dtsch Med Wochenschr, 2010. **135**(17): p. 848-852.

- 36. Thomas, L., Labor und Diagnose: Indikation und Bewertung von Laborbefunden für die medizinische Diagnostik. 7. Auflage ed. 2007: Th-Books.
- 37. RKI, Mitteilung der Ständigen Impfkommission (STIKO) am Robert Koch-Institut: Hinweise zu Impfungen für Patienten mit Immundefizienz. 2005, Robert Koch-Institut (RKI).
- 38. RKI, Empfehlungen der Ständigen Impfkommission (STIKO) am Robert Koch-Institut/Stand: August 2015. 2015, Robert Koch-Institut (RKI).













Figure 5 (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

N = 197

N = 196

N = 197

۸ ۱

A)	i	AUC
Cmax IM _{cun} Features (EP)	1.37 (P < 0.001) ***	AUC 0.68
	1.19 (P = 0.004) **	0.65
Cmax IM Features (EP)	1.28 (P = 0.003) **	
Cmax IM _{Clin} Features (VEP)	2.10 (P = 0.025) *	0.65
Facial Edema [S1–3vs. S0] (EP)	2.31 (P = 0.011) *	0.63
\geq 1 ELVIS Criterion [pos. vs. neg.](HP)		0.63
Facial Edema [S1–3vs. S0] (VEP)	1.94 (P = 0.043) *	0.62
Major Infection [pos. vs. neg.] (HP)	3.28 (P = 0.003) **	0.62
Cmax IM Features (VEP)	11.15 (P = 0.022) *	0.62
Other GI Symptoms [S2-3 vs. S0-1] (VEP)	3.42 (P = 0.027) *	0.61
Other GI Symptoms [S2–3 vs. S0–1] (EP)	3.08 (P = 0.021) *	0.60
-	2.5 5.0 7.5 10.0	

B)

В)	!	AUC	
Cmax IM _{Clin} Features (EP)	1.56 (P <0.001) *** -	0.74	N = 181
Cmax IM Features (EP)	1.22 (P = 0.007) **	0.69	N = 181
Cmax IM _{Clin} Features (VEP)	1.41 (P = 0.001) **	0.69	N = 181
MusculoskeletalSymptoms [S1–3 vs. S0] (EP)	3.61 (P = 0.003) **		N = 180
	2.98 (P = 0.006) **	0.69	N – 160
\geq 1 ELVIS Criterion [pos. vs. neg.](HP)		0.68	N = 181
≥8 Minor Infections/a [pos.vs.neg.](HP)	4.85 (P = 0.002 **)	0.67	N = 181
Exanthema[S1–3vs. S0] (EP)	3.16 (P = 0.006) **	0.66	N = 181
Cmax IM Features (VEP)	1.17 (P = 0.033) *	0.65	N = 181
Other GI Symptoms [S2-3 vs. S0-1] (EP)	3.92 (P = 0.009) **	0.65	N = 181
Other GI Symptoms [S2-3 vs. S0-1] (VEP)	3.54 (P = 0.034) *	0.64	N = 180
-	5 10 Odds Ratio		

Odds Ratio

medRxiv preprint doi: https://doi.org/10.1101/2024.05.17.24307333; this version posted May 17, 2024. The copyright holder for this preprint Supplementations holds ficine by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.









SupplemedRxiv preprint doi: https://doi.org/10.1101/2024.05.17.24307333; this version posted May 17, 2024. The copyright holder for this preprint A) It is made available under a CC-BY-NC-ND 4.0 International license . S1 S2 S3 S4